Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $25.00 price target on SI-BONE Inc. (NASDAQ:SIBN) following the company’s second-quarter 2025 financial results. According to InvestingPro data, analyst targets for SIBN range from $20 to $32, with the stock currently trading at $15.68.
SI-BONE reported second-quarter revenue of $48.6 million, exceeding both Cantor Fitzgerald’s and FactSet consensus estimates of $48.1 million. This represents year-over-year growth of approximately 22%, driven primarily by U.S. revenue which grew approximately 23% year-over-year to $46.4 million. The company maintains strong financial health with a GOOD rating on InvestingPro, supported by robust liquidity metrics and consistent revenue growth of 22.93% over the last twelve months.
The medical device company expanded its reach to over 1,440 active U.S. surgeons in the quarter, a year-over-year increase of approximately 25%. Sales representatives achieved production of approximately $2.1 million, up approximately 23% compared to the same period last year.
SI-BONE has increased its full-year 2025 revenue guidance, citing early success with its iFuse TORQ TNT product, which is performing ahead of expectations. The product will receive finalized NTAP reimbursement of approximately $4,100 per case starting in the fourth quarter of 2025.
The company plans to roll out a new SI Joint product in the first half of 2026, which is expected to further expand engagement with interventionalists, a community where adoption continues to build.
In other recent news, SI-BONE Inc. reported strong second-quarter 2025 earnings, surpassing analyst expectations. The company achieved an earnings per share (EPS) of -$0.14, which was better than the forecasted -$0.18, representing a 22.22% surprise. Revenue for the quarter reached $48.6 million, exceeding projections of $46.72 million. This revenue figure also showed a 22% growth, with U.S. revenue specifically increasing by 23%. Following these results, Canaccord Genuity raised its price target for SI-BONE to $26, maintaining a Buy rating. Jefferies also increased its price target to $28, citing the strong quarterly performance. SI-BONE achieved its third consecutive quarter of positive adjusted EBITDA and reached cash flow positivity sooner than expected. These developments highlight the company’s ongoing financial improvements and positive outlook according to analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.